A folk remedy: Royal jelly improves lung capacity in smokers by Taşdoğan, Ali Muhittin et al.
A folk remedy: royal jelly improves lung capacity in smokers
Ali Muhittin Taşdoğan1, Ebru Tarıkçı Kılıç2, Zarife Pancar2, Mustafa Özdal3
1Hasan Kalyoncu University, Medical Faculty Anesthesiology and reanimation, Gaziantep, Turkey; 2Health Sciences University 
Ümraniye Training and Research Hospital Anesthesiology and Reanimation, Ümraniye İstanbul - E-mail: ebru.tarkc@yahoo.com; 
3Gaziantep University, Sport Science Faculty, Gaziantep, Turkey
Summary. Background and Aim: Royal jelly (RJ) is one of the natural, valuable curative bee productdue to its 
promising health-beneficial and nutritional properties. This healthy diet possesses anti-inflammatory, anti-
microbial, antioxidants, antitumor, and immunomodulatory functions which benefit in humans health and 
welfare,resulting in its widespread medical use. The aim of this randomized case controlled study was to 
determine the effect of royal jelly on the lung capacity of sedentary male smokers. Materials and Methods: The 
study was approved by the ethics committee of the university and consisted of 83 sedentary male and single 
participants aged 25-30 years without any health problems. Participation was voluntary. This case controlled 
design study was conducted in accordance with the ethical principles outlined by the World Medical As-
sociation’s Declaration of Helsinki. Written informed consent was obtained from participants. The sample 
was divided into four groups: smoker experimental (Group I: 22), non-smoker experimental (Group II: 21), 
smoker control (Group III: 20), and non-smoker control (Group IV: 20). The experimental groups con-
sumed 1000 mg/day pure royal jelly between 08.00 and 10.00 am for 21 days. The control groups consumed 
a placebo liquid between 08.00 and 10.00 am for 21 days. Pre- and post-pulmonary function tests (PFTs) 
were performed. Results: Group I had significantly higher mean posttestforced expiratory volume in one 
second(FEV1) (1.86±0.19 L) than mean pretest FEV1 (1.76±0.05 L) while Group II had significantly higher 
mean posttest FEV1 (2.25±0.27 L) than mean pretest FEV1 (2.18±0.17 L) (p < 0.000). No statistically sig-
nificant difference was observed in the control groups. Conclusion: PFT results before and after 1000mg/day 
royal jelly supplement revealed positive and significant differences.
Key words: royal jelly, sedentary, smoking, pulmonary function tests, FEV1
Progress in Nutrition 2020; Vol. 22, N. 1: 297-303    DOI: 10.23751/pn.v22i1.9189                   © Mattioli 1885
O r i g i n a l  a r t i c l e
Introduction
Royal jelly is a substance secreted by honey bees to 
feed especially the queen larvae, hence the name royal 
jelly. Its health benefits were discovered in the 1600s. 
Royal jelly is a secretion of the hypopharyngeal glands 
of 5-10-day-old honeybee workers. It is pellet-like and 
has a distinct smell and bitter taste. Worker bees be-
gin to synthesize protein in the hypopharyngeal glands 
about four days after they are hatched. Protein synthesis 
continues to increase for eight days, reaches its maxi-
mum level on the fourteenth day and starts to decrease 
from the seventeenth day on (1, 2). Royal jelly is milky 
when secreted and delivered to the oral cavity but it 
turns dark and creamy after being placed in honeycomb 
cells. It is a yogurt-like homogeneous substance with 
the consistency of a fluid paste which, however, becomes 
more viscous when stored at room temperature or in a 
refrigerator at 5°C. It contains proteins, lipids, carbohy-
drates, ash, P, Na, K, Ca, Mg, pollen, and C, D and E 
and B, and many other vitamins (3, 4). 
It also contains 10-hydroxydecanoic acid (10-
HDAA), 10-hydroxydecanoic acid (10-HDAA) and se-
bacic acid (SEA) which exhibit broad-spectrum activity 
against numerous bacteria and fungi (5). The proteins in 
royal jelly are antioxidants used in the treatment of such 
diseases as cancer, atherosclerosis, hypertension, infer-
tility, asthma, depression, and diabetes mellitus resulting 
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from oxidative stress caused by the imbalance between 
reactive oxygen species (6). It also plays a key role in cell 
renewal, regeneration, and organization, and antiaging, 
and lowers blood cholesterol, total lipid, phospholipid, 
triglyceride, beta lipoprotein levels, and blood pressure, 
and dilates vessels. It has also been reported for many 
years that royal jelly exhibits antimicrobial and insulin-
like hypoglycemic and immunological activities, has 
therapeutic properties for skin and hair, and reproduc-
tive diseases, regulates sexual functions, and repairs and 
rejuvenates cells (7-9).
Royal jelly is used more and more in daily diet and 
in the treatment of many diseases. With these superior 
properties, royal jelly is becoming increasingly impor-
tant for health and is studied more extensively.
Smoking increases airway resistance during res-
piration. Thenicotine in cigarettes causes bronchioles 
to contract, and carbon monoxide in the smoke is 
bound by hemoglobin and hence reduces blood oxy-
gen carrying capacity. Research shows that smoking is 
a dominant predictor of airway obstruction. Pulmo-
nary function test (PFT) values should be measured 
to determine airway obstruction. PFTsare widely used 
to understand and rate the abnormalities in respira-
tory system functions. The air entering and leaving the 
lungs should be able to move fast enough and play a 
decisive role in physical capacity.Air velocity depends 
on theairway resistanceof chest and lung tissues, af-
fecting dynamic measurements (10, 11).
1) FVC (forced vital capacity) is the maximum amount 
of air exhaledafter a maximum inhalation.There is 
little or no difference between VC and FVC in nor-
mal subjects.
2) FEV1 (forced expiratory volume in one second) is 
the maximum amount of air expelled during the first-
second after a maximum inhalation.This is the most 
commonly used value to measure lung function. Ex-
ercise-induced bronchoconstriction (EIB) diagnosis 
requires a ≥ 10% fall in FEV1 after exercise.
3) FEV1/FVC ratio is the ratio of the forced expiratory 
volume in the first second to the forced vital capacity 
of the lungs. It is normally 80–90% and goes below 
70% in the case of obstructive pulmonary diseases.
The aim of this study was to determine the effect 
of royal jelly on the pulmonary functions of sedentary 
male smokers aged 25-30 years.
Material and Method
The study was approved by the ethics commit-
tee of the university. The study sample consisted of 83 
sedentary single male participants aged 25-30 years 
without any health problems between January and 
February 2019. Participants were asked whetherthey 
had any lung disease in the past or now, whether they 
smoked and how many cigarettes they smoked per day, 
how long they had been smoking, and whether they 
were performing physical activity or not. The exclusion 
criteria were (1) being diagnosed with a disease affect-
ing respiratory functions, (2) receiving bronchodilator 
therapy, (3) having a neuromuscular and/or cardio-
pulmonary disease, (4) having undergone abdominal 
and thoracic surgery, (5) using alcohol and drugs, and 
(6) refusing to participate in the study. The smoker 
groups consisted of those who had been smoking for 
at least 5 years and 10 to 20 cigarettes per day. The 
non-smoker groups consisted of those who had never 
smoked before. Participants were randomly assigned 
to four groups: smoker experimental (Group I: 22), 
non-smoker experimental (Group II: 21), smoker con-
trol (Group III: 20), and non-smoker control (Group 
IV: 20). Anthropometric measurements were per-
formed before intervention. Body weight was recorded 
in light clothing and height without shoes. Body mass 
index (BMI) was calculated by dividing weight (Kg) 
by the square of height (m). The experimental groups 
consumed 1000 mg/day pure royal jelly in glass vials 
between 08.00 and 10.00 am for 21 days. The con-
trol groups consumed a placebo liquid in glass vials 
between 08.00 and 10.00 am for 21 days. The medi-
cations were stored in boxes labeled as A and B. The 
participants were blinded to the allocation throughout 
the study period and were educated to follow a healthy 
lifestyle. Participants were instructed not to engage in 
any exercise or activities requiring physical strength 
for 21 days. Daily dietary intake data were evaluated 
at baseline and at the end of the study by 2 days; 1 
in the week day 1 in the weekend days by a dietician 
blinded to the study. They were followed up every week 
to check the side effects if any and for the compliance. 
Pre- and post- PFTs were performed using spirom-
etry. VC (L), FVC (L), FEV1 (1), and FEV1/FVC (%) 
were calculated.
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During the measurements, participants were seat-
ed in an upright position on a fixed chair, and their 
nostrils were occluded with a nose clip to prevent them 
from breathing through their nose. They were asked to 
inhale and exhale through their mouth three times fol-
lowed by a maximum inspiration and then maximum 
expiration. The best value was recorded after three 
consecutive repetitions. The PFTs were performed by 
another researcher blinded to the study protocol.
Statistical Analysis
Scale parameters were described by means and 
standard deviations. Normality of parameters were 
tested with Kolmogorov Smirnov Test. One Way 
ANOVA test was used for normally distributed pa-
rameters, and Kruskal Wallis Test was used for non-
normal distributed parameters. Mann Whitney U test 
was used for post hoc test of nonparametric differ-
ences. All analysis were performed at SPSS 17.0 for 
windows at 95% confidence interval. 
Results
Of participants, 42 were smokers (at least five 
years and 10-20 cigarettes per day) while the remain-
ing 41 were non-smokers. All the participants were 
male, single and all of them have academic educational 
status. In the study flow diagram; the randomization 
and the loss to follow up are presented (Fig1). 
In the study period no participants reported any 
side effects. 
Table 1 shows the groups’ demographic data, in-
dicating no statistically significant difference in age, 
BMI, or in daily dietary intake between the groups (p 
> 0.05).When the pretest and post test results (PFTs) 
were examined in terms of lung function parameters 
such as VC, FVC, FEV1, it was found that the meas-
ured values improved significantly in Group I and 
Group II (p: 0.000) Table 2
Pretest results of Group I were; 2.31 ± 0.08 L 
for VC, 2.34 ± 0.08L for FVC, 1.76 ± 0.05 for FEV1 
whereas the improved results were found as 2.41 ± 0.19 
L, 2.43 ± 0.21L, and 1.76 ± 0.05 as shown in Table 3. 
The pretest results were 2.83 ± 0.07 L for VC, 
2.71 ± 0.04L for FVC, 2.18 ± 0.17 for FEV1 for Group 
II whereas improved results after royal jelly were found 
Table 1. Demographic parameters of the groups
Pretest, Mean±SD Group I (n=22) Group II (n=21) Group III (n=20) Group IV (n=20) P value
Age 27,27±1,64 26,62±1,28 27,20±1,67 26,60±1,35 0.369b 
BMI 23,73±1,49 23,71±1,71 23,55±1,70 23,20±1,58 0.702b
Energy 2328,77±22,25 2324,10±22,23 2326,50±24,38 2325,60±25,42 0.872b
Carbonhydrate 243,23±8,28 242,81±6,07 242,05±7,78 243,25±8,36 0.955a
Protein 66,82±1,65 67,19±1,78 66,95±1,73 67,15±1,98 0.894b
Total fat 115,73±1,86 115,71±1,93 115,45±2,06 115,90±1,71 0.934b
a. One Way ANOVA Test, b. Kruskal Wallis H Test, SD: Standard Deviation. BMI: Body Mass Index. P value < 0.05 is considered statisti-
cally significant.
Figure 1: The flow Diagram 
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as 2.86 ± 0.05L for VC, 2.78 ± 0.09 L for FVC, and 
2.25 ± 0.27 for FEV1. respectively.
In other words, Royal Jelly reduced the difference 
between the initial pulmonary function capacities of 
smokers and nonsmokers.
Table 4 presents the pretest results of PFT.The 
main comparison was made between the smokers and 
nonsmokers. There was no statistically significant dif-
ference in pretest measured VC, FVC, and FEV1 val-
ues between Group II and Group IV and Group I and 
Group III  (p >0.05).
There was no statistically significant difference in 
posttest measured VC, FVC, and FEV1 values between 
Group I and Group III (p > 0.05). However, Group II 
had significantly higher FVC value than Group IV (p 
< 0.05) Table 5.
Figure II shows the pretest FEV1/FVC ratios 
of the groups. Non-smokers (Groups II and IV) had 
higher pretest FEV1/FVC ratio than smokers (Groups 
I and III). Group II had higher pretestFEV1/FVC ra-
tio than Group IV.
Figure III shows the pretest FEV1/FVC ra-
tios of the groupsNon-smokers (Groups II and IV) 
had higher posttest FEV1/FVC ratio than smokers 
(Groups I and III). Among non - smokers Group II 
had higher posttestFEV1/FVC ratio than Group IV 
whereas Groups I and III had high range.
Discussion
Research shows that cigarette smoking causes res-
piratory impairment not only at older ages but also at 
younger ages. Smoking leads to two physiopathological 
changes in the lungs; (1) the proteolytic destruction of 
lung parenchyma and emphysema, which is abnormal 





   (n=21)
Group III
   (n=20)
Group IV
  (n=20) P value
VC 2.31±0.08 2.83±0.07 2.29±0.07 2.84±0.07 0.000b
FVC 2.34±0.08 2.71±0.04 2.32±0.08 2.71±0.03 0.000b
FEV1 1.76±0.05 2.18±0.17 1.74±0.05 2.14±0.05 0.000b
a. One Way ANOVA Test, b. Kruskal Wallis H Test, SD: Standard Deviation. 










VC 2.41±0.19 2.86±0.05 2.31±0.07 2.83±0.07 0.000b
FVC 2.43±0.21 2.78±0.09 2.34±0.10 2.72±0.04 0.000b
FEV1 1.86±0.19 2.25±0.27 1.77±0.06 2.13±0.08 0.000b
a. One Way ANOVA Test, b. Kruskal Wallis H Test, SD: Standard Deviation. VC: Vital capacity, FVC: Forced vital capacity, FEV1: Forced 
expiratory volume in one second. P value < 0.05 is considered statistically significant
Table 4. Pretest Comparison of the groups
Pre-test , p values VC FVC FEV1 FEV1/FVC
Group I- Group II 0.000 0.000 0.000 0.000
Group I- Group III 0.399 0.472 0.367 0.658
Group I- Group IV 0.000 0.000 0.000 0.000
Group II- Group III 0.000 0.000 0.000 0.000
Group II-Group IV 0.606 0.679 0.548 0.712
Group III- Group IV 0.000 0.000 0.000 0.000
VC: Vital capacity, FVC: Forced vital capacity, FEV1: Forced expi-
ratory volume in one second.
Table 5. Posttest Comparison of the groups
Post-test, p values VC FVC FEV1 FEV1/FVC
Group I- Group II 0.000 0.000 0.000 0.171
Group I - Group III 0.180 0.323 0.253 0.867
Group I - Group IV 0.000 0.000 0.000 0.068
Group II - Group III 0.000 0.000 0.000 0.084
Group II - Group IV 0.197 0.048 0.260 0.894
Group III- Group IV 0.000 0.000 0.000 0.005
VC: Vital capacity, FVC: Forced vital capacity, FEV1: Forced expi-
ratory volume in one second. 
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permanent enlargement of air spaces, and chronic ob-
structive lung damage and (2) inflammatory constric-
tion of peripheral airways characterized by excessive 
edema, mucus release and peripheral airway fibrosis. 
Smoking increases airway resistance and causes pro-
longed expiration (12, 13). Free radicals increase during 
chronic inflammation, and the balance between oxidant 
and antioxidant is adversely affected, resulting in oxida-
tive stress. Smokers have low blood antioxidant capacity. 
This may not only be due to oxidative stress, but also 
because it circulates, and therefore, has a systemic ef-
fect. Smoking is associated with a reduction in erythro-
cyte glutathione peroxidase activity, serum antioxidant 
activity, and plasma ascorbic acid, vitamin E, B caro-
tene, uric acid and selenium levels. There is an increase 
in the amount of superoxide produced by neutrophils 
in peripheral blood and a decrease in total antioxidant 
capacity, especially during the attack and exacerbation 
episodes of COPD and asthma (14-16).
The harmful effects of smoking on the respiratory 
system emerge at later ages and is directly proportional 
to pack-year. Our participants were young and had low 
pack-year and therefore had normal PFT values. It is 
known that PFT cannot be used to detect early changes 
in the small airways, which is supported by some stud-
ies. Karimi et al. (17) reported that the prevalence of 
asymptomatic people with normal PFT values was high 
among smokers and that early changes in the small air-
ways could be detected by assessing the levels of air trap-
ping in the lungs using computed tomography (CT).
Present analysis demonstrates that there is a posi-
tive correlation between royal jelly consumption and 
lung functions. In vitro studies show that 10H2DA,10-
HDAA, and SEA fatty acids in royal jelly reduce the 
release of nitric oxide, IL 10 and TNF alpha (dose-
dependent major inflammatory mediators) and that 
C, D, A, and E vitamins in it protect lung tissue from 
harmful oxidative damage. AEOL150 was intratra-
cheally administered 6 hours a day, 3 days a week to 
rats exposed to filtered air (control group) or cigarette 
smoke (experimental group) to test whether cigarette-
induced inflammation would be reduced by a catalytic 
antioxidant. The number of cells in the bronchoalveolar 
lavage of the experimental group rats was significantly 
reduced. A significant reduction was observed in necro-
phils and lymphocytes in two days and in macrophages 
and lymphocytes in eight weeks. At 8 weeks, squamous 
cell metaplasia was 12% and 2% of the total airway epi-
thelial area in the control and experimental rats, respec-
tively (18).
Antioxidants protect tissues from harmful oxida-
tive damage. Diet is the most important source of anti-
oxidants. The combined activity of dietary antioxidants 
is probably superior to the individual effect of each anti-
oxidant drug, supporting the hypothesis that royal jelly 
shows strong antioxidant properties due to the additive 
effect of its antioxidants (19, 8).
Figure 2: Pretest values of FEV1/FVC
Figure 3: Posttest values of FEV1/FVC
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Vitamin C, which is found in tissues and liquids 
with high potential for free radical production, con-
tributes to antioxidant defense by primarily removing 
peroxyl and oxygen radicals. One of the mechanisms 
explaining the protective effects of vitamin C on lung 
function is as follows: Vitamin C is an important anti-
oxidant in the liquid that covers the surface of the air-
ways. Proteases and antiproteases in that fluid protect 
the epithelial and immune cells from oxidant attack. 
Low vitamin C content affects the activity of pulmo-
nary antioxidant defense systems negatively. Royal jelly 
is a rich source of vitamin C and therefore an important 
bioactive compound. Vitamin C protects the body from 
smoke-induced airway inflammation and lung dam-
age and from oxidant air pollutants such as ozone and 
nitrogen dioxide and also slows down the rate of lung 
function (FEV1) decline in adults. It has recently been 
reported that vitamins A and E also slow down the rate 
of decline in FEV1 and protect respiratory functions in 
smokers. Royal jelly is rich in vitamins A and E (20-22).
Our literature review showed that there are many 
studies reporting positive effects of royal jelly on the 
lungs.El Aidy et al. (23) found that royal jelly and propo-
lis had a positive anti-inflammatory effect on allergic 
asthma and pulmonary fibrosis in albino rats.Arajua et 
al. (24) also showed that 1 gram/kg/day royal jellyled to 
a decrease in the number of Th1-mediated cells and an 
increase in the number of Th2-mediated cells in the pe-
ripheral blood and lungs in people with asthma. Studies 
argue that royal jelly does that by scavenging free radicals.
Zargar et al. (25) investigated the effect of roy-
al jelly on pulmonary fibrosis induced by bleomycin. 
They reported that 50-100 mg/kg royal jelly acted 
as a protective mechanism in bronchoalveolar lavage 
samples by reducing TGF-β, TNF-α cytokines, and 
chemotaxis of inflammatory cells and by increasing 
INF-γ, an antifibrotic cytokine. They also showed his-
topathologically that royal jelly provided macroscopic 
improvement.
TNF-α has both inflammatory and fibrogenic 
properties and is responsible for the development of 
airway obstruction, inflammation and pulmonary fi-
brosis. Intracellular studies have shown that MRJP3, 
a major protein in royal jelly, reduces TNF-α produc-
tion. IFN-γ prevents fibroblast activation. In vitro 
studies have shown that IFN-γ has an inhibitory effect 
on TGF-β signaling pathways. Zargar (25) showed 
that TGF-β level decreased in royal jelly consumers.
Kamiya et al. (26) conducted an intracellular study 
of the proapoptoticactivities of royal jelly and reported 
that HPO-DAEE, a fatty acid of royal jelly, induced 
apoptosis of A549 cells.They argued that intracellular 
ROS activated by HPO-DAEE played a role in the 
destruction of cancer cells. Further research is war-
ranted detailing the chemical structure and clinical ap-
plication of HPO-DAEE in royal jelly.
In conclusion, proteins, proapoptoticfatty acids, 
vitamins, and numerous antioxidants in royal jelly can 
prevent smoking-induced airway obstruction and fi-
brosis in the early period, and PFTs can yield posi-
tive results before there arises a shift in the balance 
between oxidants and antioxidants in favor of oxidants.
The strength of our clinical trial is randomized 
and controlled design without inter individual differ-
ences however has two main limitations; (1) the sam-
ple consisted only of young male participants and (2) 
smoking participants had a low pack-year history in 
a short intervention time. Further studies with larger 
sample sizes with different dosages and durations are 
needed to provide more evidence regarding the posi-
tive effects of royal jelly on pulmonary function.
Conclusion
Royal Jelly is associated with the improvement in 
lung function even in young smokers with intact oxi-
dant/antioxidant balance and a low pack-year smoking 
history, however, it is misleading.
Finally, Royal jelly at moderate concentrations has 
come into promising interest with many health benefits 
in medicine. Future in vitro trials on respiratory physiol-
ogy are needed.
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